Breaking News Instant updates and real-time market news.

AVXS

AveXis

$115.91

-3.69 (-3.09%)

, NVS

Novartis

$80.20

-0.86 (-1.06%)

08:26
04/09/18
04/09
08:26
04/09/18
08:26

Bernstein not too surprised with AveXis sale

Bernstein analyst Vincent Chen notes that Novartis (NVS) and AveXis (AVXS) announced an agreement for the former to purchase AveXis for $218 per share, a total of $8.7B. The analyst says he has long suspected he would see acquisitions in gene therapy and that AveXis could be a prime candidate, so he is not too surprised to see it go. However, the analyst acknowledges that he had not pegged Novartis as the top contender. Noting that the announcement should be a positive for others in the space, Chen reiterates an Outperform rating and $144 price target on AveXis shares.

AVXS

AveXis

$115.91

-3.69 (-3.09%)

NVS

Novartis

$80.20

-0.86 (-1.06%)

  • 23

    Apr

  • 17

    May

AVXS AveXis
$115.91

-3.69 (-3.09%)

04/09/18
MZHO
04/09/18
DOWNGRADE
MZHO
Neutral
AveXis downgraded to Neutral from Buy at Mizuho
Mizuho downgraded AveXis (AVXS) to Neutral following the acquisition by Novartis (NVS) for $218 per share in cash.
04/09/18
FBCO
04/09/18
NO CHANGE
Target $170
FBCO
Outperform
AveXis price target raised to $170 from $139 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for AveXis to $170 from $139 to reflect his growing confidence in AVXS-101's ability to treat the broader SMA incidence population, which drives an incremental $200M in annual revenue. The analyst reiterates an Outperform rating on the stock.
02/28/18
FBCO
02/28/18
NO CHANGE
Target $139
FBCO
Outperform
AveXis price target raised to $139 from $134 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for AveXis to $139 from $134 following a "strong" Q4 and as he believes pipeline poised to contribute. The analyst reiterates an Outperform rating on the shares.
02/28/18
WELS
02/28/18
NO CHANGE
Target $171
WELS
Outperform
AveXis price target raised to $171 from $134 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for AveXis to $171 from $134 following review of Q4 progress and on the outlook for its SMA gene therapy and broader pipeline 2018. Overall, the analyst continues to expect approval of AVXS101 gene therapy for type 1 SMA by YE18, and with progress in broader development for type 2 SMA and pre-symptomatic patients with type 1, 2 and 3 SMA, he sees a potential recurring patient population of 5000 patients and $10B in market opportunity, and significant upside potential. Birchenough reiterates an Outperform rating on the shares.
NVS Novartis
$80.20

-0.86 (-1.06%)

03/21/18
WELS
03/21/18
NO CHANGE
WELS
Outperform
Amphastar court win a 'major' positive, says Wells Fargo
Wells Fargo analyst David Maris called the news of Massachusetts' District Court entering a final judgement in favor of Amphastar (AMPH) in the patent lawsuit regarding Lovenox brought by Momenta (MNTA) and Novartis' (NVS) Sandoz division a "major positive" that again demonstrates Amphastar's ability to face down larger, better-funded companies and get difficult products to market. He maintains an Outperform rating on Amphastar shares.
03/02/18
OPCO
03/02/18
INITIATION
Target $16
OPCO
Outperform
Conatus initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson initiated Conatus (CNAT) with an Outperform rating and $16 price target based on his view that significant value for shareholders, physicians and patients can be unlocked by the company's "unique" approach to liver disease. In a research note to investors, Olson said he sees emricasan as well positioned to potentially demonstrate efficacy in a broad range of liver diseases, including NASH, adding that the program is viewed as "partially de-risked" through its partnership with Novartis (NVS).
02/12/18
LEER
02/12/18
NO CHANGE
Target $502
LEER
Outperform
Data from Regeneron Eylea competitors should lift some overhang, says Leerink
Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $65
RBCM
Outperform
Spark Therapeutics assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed coverage of Spark Therapeutics (ONCE) with an Outperform rating and a price target of $65. MacKay says the FDA approval of Luxturna and "ex-Novartis (NVS) collaboration" helps to de-risk the company's earlier-stage hemophilia and inherited retinal disease assets, calling Spark Therapeutics a "trailblazer in the gene therapy space".

TODAY'S FREE FLY STORIES

TWTR

Twitter

$29.24

-1.24 (-4.07%)

14:05
04/25/18
04/25
14:05
04/25/18
14:05
Upgrade
Twitter rating change  »

Twitter upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

  • 27

    Jul

TMUS

T-Mobile

$63.95

1.37 (2.19%)

14:05
04/25/18
04/25
14:05
04/25/18
14:05
Options
T Mobile call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPKE

Spark Energy

$11.78

0.025 (0.21%)

14:04
04/25/18
04/25
14:04
04/25/18
14:04
Periodicals
Breaking Periodicals news story on Spark Energy »

Spark Energy said to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 10

    May

ACAD

Acadia

$19.95

0.47 (2.41%)

14:00
04/25/18
04/25
14:00
04/25/18
14:00
Periodicals
FDA head says will 'take another look' at Acadia's Nuplazid, CNN reports »

In response to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$304.83

-2.41 (-0.78%)

13:58
04/25/18
04/25
13:58
04/25/18
13:58
Conference/Events
Netflix management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

MSFT

Microsoft

$92.23

-0.85 (-0.91%)

13:55
04/25/18
04/25
13:55
04/25/18
13:55
Conference/Events
House Appropriations Committee to hold a hearing »

The Labor, Health &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

ZOOM

Zoom Technologies

13:55
04/25/18
04/25
13:55
04/25/18
13:55
Conference/Events
Zoom Technologies participates in a conference call with RBC Capital »

RBC Capital Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JD

JD.com

$35.84

-0.03 (-0.08%)

13:50
04/25/18
04/25
13:50
04/25/18
13:50
Options
Volatility play in JD as January puts trade in large blocks Wednesday »

Volatility play in JD as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
04/25/18
04/25
13:50
04/25/18
13:50
General news
Treasury Curve Action: steepeners resumed »

Treasury Curve Action:…

AMD

AMD

$9.69

-0.4 (-3.96%)

13:40
04/25/18
04/25
13:40
04/25/18
13:40
Options
Aggresive buyer lays out $2.2M for deep in the money Advanced Micro puts »

Aggresive buyer lays out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

AAPL

Apple

$164.70

1.83 (1.12%)

13:40
04/25/18
04/25
13:40
04/25/18
13:40
Conference/Events
President Trump to meet with Apple CEO Cook »

The meeting between…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 01

    May

WELL

Welltower

$49.86

-1.16 (-2.27%)

, QCP

Quality Care Properties

$21.35

0.55 (2.64%)

13:37
04/25/18
04/25
13:37
04/25/18
13:37
Periodicals
Promedica, Welltower offering $2B to aquire Quality Care Properties, Reuters says »

Promedica and Welltower…

WELL

Welltower

$49.86

-1.16 (-2.27%)

QCP

Quality Care Properties

$21.35

0.55 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 03

    May

  • 04

    May

EBAY

eBay

$40.63

-0.55 (-1.34%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Technical Analysis
Technical Earnings Preview: eBay in uptrend ahead of earnings »

The shares have been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LC

LendingClub

$2.78

-0.485 (-14.85%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Hot Stocks
LendingClub calls charges in FTC complaint 'legally and factually unwarranted' »

Following an inquiry that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

LC

LendingClub

$2.78

-0.485 (-14.85%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Hot Stocks
Breaking Hot Stocks news story on LendingClub »

LendingClub calls charges…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

FB

Facebook

$160.15

0.49 (0.31%)

, GOOG

Alphabet

$1,021.04

1.58 (0.15%)

13:35
04/25/18
04/25
13:35
04/25/18
13:35
Periodicals
Facebook declines to testify at U.S. House hearing on social media, Reuters says »

A Facebook (FB) spokesman…

FB

Facebook

$160.15

0.49 (0.31%)

GOOG

Alphabet

$1,021.04

1.58 (0.15%)

GOOGL

Alphabet Class A

$1,023.95

0.97 (0.09%)

TWTR

Twitter

$28.98

-1.5 (-4.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 30

    May

  • 27

    Jul

HOG

Harley-Davidson

$41.88

-0.13 (-0.31%)

13:30
04/25/18
04/25
13:30
04/25/18
13:30
Options
Hefty spread opened in Harley Davidson options »

Hefty spread opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

TWTR

Twitter

$28.97

-1.51 (-4.95%)

13:29
04/25/18
04/25
13:29
04/25/18
13:29
Recommendations
Twitter analyst commentary  »

Twitter outlook looks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

  • 27

    Jul

XOM

Exxon Mobil

$78.56

0.21 (0.27%)

13:29
04/25/18
04/25
13:29
04/25/18
13:29
Hot Stocks
Exxon Mobil boosts Q2 dividend to 82c from 77c »

Exxon Mobil's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FB

Facebook

$160.04

0.38 (0.24%)

13:25
04/25/18
04/25
13:25
04/25/18
13:25
Technical Analysis
Technical Earnings Preview: Facebook in an active bearish pattern before news »

There is a bearish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MGM

MGM Resorts

$35.36

-0.16 (-0.45%)

13:25
04/25/18
04/25
13:25
04/25/18
13:25
Options
MGM Resorts call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CBLK

Carbon Black

13:25
04/25/18
04/25
13:25
04/25/18
13:25
Conference/Events
Cowen software analyst to hold an analyst/industry conference call »

Infrastructure &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

BA

Boeing

$338.10

9.1 (2.77%)

13:23
04/25/18
04/25
13:23
04/25/18
13:23
Upgrade
Boeing rating change  »

Boeing upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

13:20
04/25/18
04/25
13:20
04/25/18
13:20
General news
Treasury Action: the OK auction hasn't really registered on Treasury screens »

Treasury Action: the OK…

TER

Teradyne

$35.36

-6.14 (-14.80%)

, AAPL

Apple

$165.05

2.18 (1.34%)

13:18
04/25/18
04/25
13:18
04/25/18
13:18
Recommendations
Teradyne, Apple analyst commentary  »

Teradyne valuation…

TER

Teradyne

$35.36

-6.14 (-14.80%)

AAPL

Apple

$165.05

2.18 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 16

    May

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.